Cronkhite-Canada syndrome (CCS) is a very rare disease with symptoms that include loss of taste, intestinal polyps, hair loss, and nail growth problems. It is difficult to treat because of malabsorption that accompanies the polyps. CCS occurs primarily in older people (the average age is 59) and it is not believed to have a genetic component. There have been fewer than 400 cases reported in the past 50 years, primarily in Japan but also in the U.S. and other countries.
The symptoms of Cronkhite-Canada syndrome include diarrhea, cramps, excessive gas, and abdominal discomfort. These symptoms occur because of multiple polyps that carpet the walls of the stomach, small intestine, and colon. People with Cronkhite-Canada syndrome may not be able to digest milk and dairy products (lactose intolerance), and have a decrease in their ability to properly absorb nutrients (malabsorption) through the small intestine. Approximately 15 percent of people with Cronkhite-Canada syndrome eventually develop cancer of the colon.
People with Cronkhite-Canada syndrome may have abnormally low levels of protein in the blood (protein-losing hypoproteinemia). This may cause a feeling of general ill health (cachexia), malnutrition, nausea, vomiting, a profound loss of appetite even to the point of malnutrition, weight-loss and/or excess fluid accumulation in the arms and legs (peripheral edema). An imbalance of certain essential minerals (electrolytes) may occur because of chronic diarrhea. Some people with Cronkhite-Canada may also have large skin bruises (ecchymotic plaques) and/or impaired lung function. Other symptoms may include loss of hair (alopecia), large areas of dark spots on the skin (hyperpigmentation) and degenerative changes and eventual loss of the fingernails (onychodystrophy).
The exact cause of Cronkhite-Canada syndrome is not known. It seems to occur for no known reason (sporadically) and is not thought to be genetic in origin.
Cronkhite-Canada syndrome is an extremely rare disorder that affects more females than males. (The ratio seems to be approximately 1.5 females to 1 male. Typically, the age of onset is during the middle years or old age. The average is about 59 years with a range of 31 to 85 years. Worldwide, fewer than 400 cases have been reported in the past 50 years, primarily in Japan but also in the United States and other countries.
Because so little is known of the cause of the disorder, treatment is symptomatic. The primary goal of treatment is to correct fluid, electrolyte and protein loss by nutritional supplementation or a nutritionally balanced liquid diet. Corticosteroid drugs (i.e., prednisone) may be given occasionally to help reduce intestinal inflammation. Bacterial overgrowth in the intestines, which can cause malabsorption, may be treated with antibiotics. In rare cases, symptoms have resolved for no apparent reason (spontaneous remission). Other treatment is symptomatic and supportive.
Surgical removal of polyps may help to relieve some of the symptoms of Cronkhite-Canada syndrome. However, they may recur or be too numerous to remove individually. If necessary, severely affected portions of the colon may be removed.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.
For information about clinical trials being conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
A research group at the University of Texas is looking for a patient diagnosed with Cronkhite-Canada syndrome to test a theory about the cause of the disease. If the theory is correct, the poorly growing fingernails will contain a substance that should give an important clue to the cause. The test requires only that the researchers obtain one or two small fingernail clippings from an affected individual (provided through his or her physician) for detailed content analysis. There is no compensation for this study, but it is hoped that the research may lead to an understanding of what causes this difficult disease and, therefore, may help guide future treatment. For information or to participate, ask your physician to contact:
The University of Texas at Austin
1 University Station A8000
Austin, Texas 78712
Phone: (512) 796-9314
Fax: (512) 472-3514
Oberhuber G, Cronkhite-Canada Syndrome. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:338.
Yamada T, Alpers DH, Owyang C, et al. Eds. Textbook of Gastroenterology. 2nd ed. J. B. Lippincott Company. Philadephia, PA; 1995:1960.
Ward EM, Wolfsen HC. Review Article: the non-inherited gastrointestinal polyposis syndromes. Aliment Pharmacol Ther. 2002;16:333-42.
Oberhuber G, Stolte M. Gastric polyps: an update of their pathology and biological significance. Virchows Arch. 200;437:581-90.
Ward EM, Wolfsen HC. Pharmacological management of Cronkhite-Canada syndrome. Expert Opin Pharmacother. 2003;4:385-89.
Egawa T, Kubota T, Otani Y, et al. Surgically treated Cronkhite-Canada syndrome associated with gastric cancer. Gastric Cancer. 2000;27:156-60.
Ward EM, Wolfsen HC, Ng C. Medical management of Cronkhite-Canada syndrome. South Med J. 2002;95:272-74.
Fossati M, Lombardi F, Cattaneo C, et al. Cronkhite-Canada syndrome. A case of sustained partial remission. Dig Liver Dis. 2001;33:785-77.
Goto A. Cronkhite-Canada syndrome: epidemiological study of 110 cases reported in Japan. Nippon Geka Hokan. 1995;64:3-14.
FROM THE INTERNET
McKusick VA, Ed. Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Entry Number; 175500: Last Edit Date; 2/25/1995.
Rabinowitz SS. Cronkhite-Canada Syndrome. eMedicine. Last Updated: January 10, 2003. 12pp.
Serwin AB, Mysliwiec H. Cronkhite-Canada Syndrome. eMedicine. Last Updated: October 22, 2001. 14pp.
Cronkhite-Canada syndrome. CHORUS-Collaborative Hypertext of radiology. Last Updated: 14 March 2001. 1p.
Cronkhite-Canada syndrome Information Page Diseases Database. Last major update: 1 Mar 2003. 3pp.
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100